Key contacts

Peter Molloy

Peter Molloy
Founding Director

Simon Bindloss

Simon Bindloss
Business Development Manager

Regional office - North America
245 Park Avenue
39th Floor
New York, NY 10167
Tel: +1 646 653 7026

listed companies

TransAtlantic Petroleum Afferro Mining
South American Silver Corp Infinity Pharmaceuticals
Exelixis Idenix
Pharmacyclics Ariad Pharmaceuticals
Arrowhead Research Corporation AVEO Pharmaceuticals
Sangamo BioSciences TransDigm Group
Array BioPharma Alnylam Pharmaceuticals
Spirit AeroSystems FLIR Systems
BioCryst Pharmaceuticals BioLineRx
Sucampo Pharmaceuticals Anthera Pharmaceuticals
See more

Companies with HQs in usa

Veris Gold Corp Nordgold
Ardea Biosciences CAE
Woulfe Mining RGI International
Altius Minerals Orbite Aluminae
Pan American Goldfields Nordion
Paladin Labs Dalradian Resources
Patheon Exact Sciences
MethylGene OPMEDIC Group
Torex Gold Canada Lithium Corporation
Xplore Technologies Corp Edgewater Exploration
See more

Latest research

Canadian General Investments

‘One-stop-shop’ for investment in Canada

Review | Investment Companies | 27/04/2017

Canadian General Investments (CGI) is registered as a Canadian investment corporation, which confers favourable tax status; it is listed on both the Toronto and London stock exchanges. Given its broad exposure to primarily Canadian equities, the fund may be considered as a ‘one-stop-shop’ for investment in Canada. CGI’s NAV total return has outperformed the S&P/TSX Composite index benchmark over one and five years. The manager’s high ownership of CGI ensures that all shareholders’…


Prize fighter

QuickView | Aerospace & Defence | 27/04/2017

Saab shares continue to go from strength to strength. Q117 results confirm the company is on track to achieve above targeted organic sales development in the near term. Order intake remains positive and prospects for the new and upgraded versions of the Gripen fighter aircraft remain strong, aided by the improving trends in defence spending. The shares are trading once again at record levels, and the rating requires a continuing conversion of the pipeline into firm activity.

Tonix Pharmaceuticals

HONOR study up and running

Update | Pharmaceutical & healthcare | 20/04/2017

Tonix Pharmaceuticals has commenced enrolment for the Phase III HONOR study of TNX-102 SL in military-related post-traumatic stress disorder (PTSD). It is expected to enroll up to 550 patients with a CAPS-5 of ≥33 upon entry. Importantly, the FDA has agreed to an interim analysis encompassing 275 patients at which point it may be stopped for efficacy. The FDA has also indicated that if the data is “statistically persuasive” only one study may be needed for approval. The interim…

Orexigen Therapeutics

Contrave comeback

Update | Pharmaceutical & healthcare | 19/04/2017

Orexigen’s decision to shift its US marketing focus from healthcare providers to consumers appears to be paying dividends as there has been a significant rebound in Contrave prescriptions since the launch of the patient-centric campaign. Outside of the US, progress continues as the product has launched in 13 countries, with another 10 expected by the end of the year, including Italy, where Orexigen just signed a local commercial and distribution partner.


Termination of coverage

Update | Pharmaceutical & healthcare | 12/04/2017

Edison Investment Research is terminating coverage on Athersys (ATHX). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Edison North America

Edison’s North American office opened in 2011 to provide research services to companies listed on North American stock exchanges. Companies of all sizes benefit from our research service, which provides the highest standards of equity research and unrivalled distribution of our reports on a global and unrestricted basis.